|
| S. no. | Drugs | Pharmaceutical or biological matrix | Stationary phase | Chromatographic conditions | Linearity (μg/ml) | Wavelength (nm) | Ref. |
|
| 1 | ALLP and LSD | Tablet | Zorbax C18 (4.6 × 150 mm × 5 μm), injection volume = 10 μL | Methanol: Phosphate buffer pH 3.9 (55 : 45v/v), flow rate = 1.0 mL min−1 | 100–500 μg mL−1 for ALLP and 1–5 μg mL−1 for LSD | 255 | [25] |
|
| 2 | ALLP and LSD | Tablet | Inertsil ODS (4.6 × 250 mm, 5 mm), injection volume = 20 μL | Trifluoroacetic acid: methanol (40 : 60v/v), flow rate = 1.0 mL min−1 | 30–150 μg mL−1 for ALLP and 20–100 μg mL−1 for LSD | 255 | [26] |
|
| 3 | ALLP and OXP | Human plasma | Reversed-phase LiChrospher 100 RP-18 column (5 m; 250 × 4 mm; Merck, Darmstadt, Germany), flow rate = 1.0 mL min−1, injection volume = 40 μL | 0.02 M sodium acetate adjusted with acetic acid 30% to pH 4.5, flow rate = 1.0 mL min−1 | 0.5–10 mg L−1 for ALLP and 1.0–40 mg L−1 for OXP | 254 | [27] |
|
| 4 | ALLP and LPA | Tablet | Reversed-phase, Enable C18 G (250X4.6X5), injection volume = 20 μL | Acetonitrile: 0.02 M ammonium acetate buffer adjusted to pH 4.6 in the proportion of 50 : 50 v/v, flow rate = 0.8 mL min−1 | 50–175 μg mL−1 for both drugs | 210 | [28] |
|
| 5 | ALLP | Tablet | C8 (250 × 4.6 mm, 5 mm), injection volume = 10 μL | 70% buffer solution (monobasic ammonium phosphate 0.05 M with 30% acetonitrile and methanol 1 : 1), flow rate = 1 mL min−1 | 10–50 μg mL−1 | 250 | [29] |
|
| 6 | ALLP and KTZ | Capsule | InertSustain® C18 column (4.6 × 100 mm) x 3 μm, injection volume = 20 μL | Acetonitrile: water (52 : 48 v/v) with pH adjusted to 3.0, flow rate of 0.45 mL min−1 | 2.0 to 16.0 μg mL−1 for ALLP and 1.0 to 15.0 μg mL−1 for KTZ | ALLP at 250, KTZ at 225 | [30] |
|
| 7 | ALLP, OXP, and UA | Urine and serum | RP (PerkinElmer RP-8, 10 pm, 250 × 4.6 mm), injection volume = 20 μL | 0.025 M phosphate buffer pH 6.1 with 6–8% of methanol, flow rate of 1.5 mL min−1 | 2–2000 ng in all matrices | +1.2 V vs. SCE for voltammetry, +0.24 V vs. Ag/AgCl for polarography, | [31] |
|
| 8 | ALLP and OXP | Human plasma and urine | Stainless steel tubes 6.35 mm (1/4 in.) OD, 4.5 mm ID, 30 mm and 70 mm long, packed with Aminex A-27 (12–15 μm) anion-exchange resin | Ammonium acetate pH 8.7 at a flow rate of 1 mL min−1 | For ALLP, 0.068–1.36 μg mL−1, 0.68–136 μg mL−1; for OXP, 0.076–15.2 μg mL−1, 15.2–304 μg mL−1 in plasma and urine, respectively | 254 | [32] |
|
| 9 | ALLP and OXP | Human serum | C18 (particle size 10 μm, Waters co., Milford, MA, USA) | 2% (v/v) acetonitrile solution-100 mm potassium phosphate (pH 4·0) and 0·5 mm tetra-n‐butylammonium hydrogen sulphate | For ALLP, 0·5–5·0 μg mL−1; for OXP, 0·4–20 μg mL−1 | 260 | [33] |
|
| 10 | HPX XN, ALLP, OXP, and UA | Urine | HPLC: C18 Altex Model 310 (Altex Instruments, Berkeley, Calif.), GC: SE-30 (4% on 100/120 mesh SUPELCOPORT) glass column, 0.2 × 180 cm | HPLC: acetonitrile-buffer (1 : 1), GC: nitrogen as carrier gas at 20 mL min−1 | 40 to 500 μg mL−1 for all samples | 254 and 280 | [34] |
|
| 11 | ALLP, OXP, HPX, XN | Urine and human plasma | ODS column (15 cm × 4.6 mm ID) and the precolumn (5 cm × 4.6 mm ID) | 0.02 M potassium dihydrogen phosphate, pH adjusted to 3.65 with orthophosphoric acid | 0.15 to 20 mg L−1 for ALLP and OXP; 0.50 to 50 μmol L−1 for HPX and XN | 254 | [35] |
|
| 12 | ALLP, OXP | Human plasma | 100 mm × 4.6 m ID and slurry packed with 5 μm Hypersil ODS | 20 mM disodium hydrogen phosphate dehydrate, pH 2.0 with orthophosphoric acid | 0·05–5·0 μg mL−1 for both drugs | 254 | [36] |
|
